Racura Oncology, RC220, EGFR-Mutant NSCLC, Non-Small Cell Lung Cancer, HARNESS-1, Osimertinib, Bisantrene, MYC, Oncology Research, Phase 1 Clinical Trial, Cancer Drug Development, Targeted Therapy

Sydney, Australia, October 12, 2026 Racura Oncology Limited has received clearance to advance its investigational cancer therapy RC220 to...